Beijing Leadman Biochemistry Co.,Ltd. (SHE:300289)
China · Delayed Price · Currency is CNY 5.64
-0.14 (-2.42%)
Oct 19, 2026, 3:04 PM CST
SHE:300289 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 16, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
| 3,068 | 3,792 | 2,666 | 3,346 | 3,134 | 4,390 | |
Market Cap Growth | -26.27% | 42.24% | -20.32% | 6.77% | -28.63% | 78.40% |
Enterprise Value | 2,187 | 2,956 | 1,945 | 2,561 | 2,341 | 3,658 |
Last Close Price | 5.64 | 6.97 | 4.90 | 6.14 | 5.75 | 8.03 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 16, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | - | - | - | 218.14 | - | 195.82 |
Forward PE | - | 30.00 | 30.00 | 30.00 | 30.00 | 30.00 |
PS Ratio | 9.65 | 11.62 | 7.20 | 7.25 | 4.44 | 7.78 |
PB Ratio | 1.84 | 2.27 | 1.55 | 1.85 | 1.76 | 2.22 |
P/TBV Ratio | 1.99 | 2.46 | 1.71 | 2.13 | 2.04 | 2.73 |
P/FCF Ratio | 182.77 | 327.59 | 80.34 | 29.84 | 44.88 | 58.88 |
P/OCF Ratio | 81.75 | 130.02 | 42.72 | 25.58 | 28.77 | 36.87 |
PEG Ratio | - | 2.14 | 2.14 | 2.14 | 2.14 | 2.14 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 16, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
EV/Sales Ratio | 6.88 | 9.06 | 5.25 | 5.55 | 3.32 | 6.48 |
EV/EBITDA Ratio | 268.23 | 220.01 | 100.37 | 32.40 | 30.45 | 29.94 |
EV/EBIT Ratio | - | - | - | 127.91 | 130.50 | 54.90 |
EV/FCF Ratio | 130.27 | 255.36 | 58.62 | 22.84 | 33.53 | 49.06 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 16, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Debt / Equity Ratio | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 |
Debt / EBITDA Ratio | 0.33 | 0.27 | 0.21 | 0.11 | 0.15 | 0.10 |
Debt / FCF Ratio | 0.16 | 0.36 | 0.15 | 0.08 | 0.17 | 0.18 |
Net Debt / Equity Ratio | -0.55 | -0.54 | -0.51 | -0.47 | -0.44 | -0.46 |
Net Debt / EBITDA Ratio | -118.95 | -66.89 | -45.70 | -10.71 | -10.24 | -7.49 |
Net Debt / FCF Ratio | -54.40 | -77.63 | -26.69 | -7.55 | -11.27 | -12.28 |
Asset Turnover | 0.18 | 0.18 | 0.20 | 0.23 | 0.33 | 0.28 |
Inventory Turnover | 2.07 | 1.97 | 2.10 | 2.13 | 4.08 | 2.98 |
Quick Ratio | 13.39 | 11.62 | 12.43 | 9.47 | 6.47 | 6.51 |
Current Ratio | 14.67 | 12.71 | 13.64 | 10.39 | 7.26 | 7.14 |
Return on Equity (ROE) | -1.63% | -1.40% | -4.21% | 1.26% | -1.92% | 2.81% |
Return on Assets (ROA) | -1.28% | -1.14% | -1.19% | 0.64% | 0.52% | 2.09% |
Return on Invested Capital (ROIC) | -4.85% | -4.09% | -4.00% | 1.90% | 1.75% | 5.02% |
Return on Capital Employed (ROCE) | -2.20% | -1.90% | -2.10% | 1.10% | 1.00% | 3.10% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 16, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Earnings Yield | -0.84% | -0.61% | -2.82% | 0.46% | -1.80% | 0.51% |
FCF Yield | 0.55% | 0.30% | 1.24% | 3.35% | 2.23% | 1.70% |
Dividend Yield | - | - | - | 0.16% | - | 0.25% |
Payout Ratio | - | - | - | 1.31% | - | 1.80% |
Buyback Yield / Dilution | -0.65% | -0.15% | 0.01% | 3.35% | -25.50% | -5.54% |
Total Shareholder Return | -0.65% | -0.15% | 0.01% | 3.51% | -25.50% | -5.29% |